Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524) After Dosing for a Second Season in Children [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports on safety, tolerability, and immunogenicity results for a second RSV prophylaxis season with Motavizumab (MEDI-524) in childr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Motavizumab (motavizumab)

Snippet

Sponsor: MedImmune LLC | Conditions: Motavizumab Administration for a Second Season for RSV Prophylaxis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2013-05-22